Belvedere Trading
XFOR icon

Belvedere Trading’s X4 Pharmaceuticals XFOR Stock Holding History

Belvedere Trading’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-959
Closed -$55.8K – 998
2023
Q2 		$55.8K Buy
+959
New +$49.3K ﹤0.01% 531

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Belvedere Trading's XFOR Position: Q3 2023 in Review

Belvedere Trading sold out of X4 Pharmaceuticals (XFOR) in Q3 2023, closing a stake of 959 shares — an estimated $55.8K sold.

Belvedere Trading first reported a position in XFOR in Q2 2023 and held it in 1 quarter. The position peaked at $55.8K in Q2 2023. 91 funds tracked by Wall St. Rank hold XFOR as of Q3 2023.

  • Belvedere Trading reported no remaining X4 Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Belvedere Trading sold 959 X4 Pharmaceuticals shares in Q3 2023, an estimated $55.8K.
  • Belvedere Trading first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Belvedere Trading's X4 Pharmaceuticals position peaked at $55.8K in Q2 2023.
  • 91 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.